Survival With Oral d&otalol in Patients With Left Ventricular Dysfunction After Myocardial Infarction: Rationale, Design,
and Methods (the SWORD Trial)
Albert L. Waldo, MD, A. John Camm, MD, H. deRuyter, MD, Peter L. Friedman, MD, PhD, Daniel J. MacNeil, MD, Bertram Pitt, MD, Craig M. Pratt, MD, Bruce E. Rodda, PhD, and Peter J. Schwartz, MD, for the SWORD Investigators*

Impaired left ventricular function after acute myocardial infarction (AMI) is associated with an increased risk of death. Despite recent advances in the management of these patients, sudden death accounts for up to 50% of this mortality, and effective treatment strategies have
et to be identified. Preliminary trials with amiodarone Kave offered promise that drugs that prolong action potential duration by blocking the potassium channel ma be useful in reducing this mortality. The Survival WiK 0~11 d-Sotalol (SWORD) trial is a multicenter, multinational study which tests the hypothesis that the class Ill agent d-sotalol will reduce all-cause mortality in high-

risk survivors of AMI. The trial will enroll 6,400 patients with left ventricular dysfunction (ejection fraction do%) and a recent (6 to 42 days) or a remote (~42 days) AMI with overt heart failure (New York Heart Association class II or Ill). In approximately 500 centers throughout the world, men and women aged 218 years will be enrolled and randomized to placebo or d-sotalol (200 mg/day). The minimal follow-up will be 18 months. The trial has a 90% power to detect a 20% reduction in allcause mortali . The rationale, design, and trial methods are descr“i6 ed.
(Am J Cardiol 1995;75: 1023-l 027)

d -Sotalol is the dextrorotatory isomer of the racemate The results of Survival With Oral d-Sotalol (SWORD) d,l-sotalol. Like the racemate,it is a classIII antia.r- will definethe role of d-sotalol asa classIII agentin this

rhythmic drug that prolongs the action potential dura- high-risk population and contribute to a more rational

tion and refractoriness of cardiac tissue by blocking the managementof thesepatients.

delayed rectifier current of the potassium channel.’ It is

antifibrillatory in some ischemic models,2 but not in METHODS

models that are associatedwith sympathetichyperactiv- Obiectives: The primary objective of SWORD is to

ity.3 Unlike d,l-sotalol, it has only minimal P-blocking determine whether d-sotalol will reduce all-cause mor-

activity in animals,4andthis activity is not clinically sig- tality compared with placebo in patients with left ven-

nificant in humans.5After oral administration, it is near- tricular dysfunction and coronary artery diseasemani-

ly 100%absorbed,and is excretedunmetabolizedby the fested by a prior AMI. It also will compare the safety

kidneys (data on file, Bristol-Myers Squibb, Princeton, and tolerance of d-sotalol and placebo when adminis-

New Jersey). In clinical trials, d-sotalol has been well tered long-term to thesepatients.

tolerated,with alow incidenceof reportedadverseevents. Design: SWORD is a multinational, multicenter, ran-

Torsadesde pointes hasoccurred in approximately 1.2% domized,double-blind, placebo-controlledtrial in approx-

of thoseexposedto the drug (data on file, Bristol-Myers imately 500 centers worldwide. The study will enroll

Squibb, Princeton, New Jersey).

6,400 men and women, aged218 years,who have a left

This report describesthe protocol of astudy that com- ventricular ejection fraction of 540% determined by

paresd-sotalol with placeboin the treatmentof high-risk either radionuclide or contrast angiography or echocar-

survivors of acute myocardial infarction (AMI). The diography performed within 6 months of randomization.

expectedtreatmentdifferencesrequire alarge study pop- In addition, thesepatients must have evidence of a pri-

ulation that necessitates a multicenter, multinational or AMI. Two such groups will be identiiied. Group 1

design. The trial provides the fist opportunity to inves- (acute group) will consist of patients with an AM1 6 to

tigate the benefit of an antiarrhythmic drug that selec- 42 daysbeforerandomization with or without overt heart

tively prolongs action potential duration by blockade of failure. Group 2 (remote group) will consist of patients

the delayed rectifier current of the potassium channel. with an AM1 occurring ~42 days before randomization

who also have a history of overt heart failure (New York

From the Division of Cardiology, University Hospitals of Cleveland, Cleveland, Ohio. This study was supported by a grant from BristolMyers Squibb, Princeton, New Jersey. Manuscript received July 22,

Heart Association functional classII or III). Criteria for anAM1 arethe presenceof 22 of the following: (1) characteristic myocardial ischemic pain in the precordium or

1994; revised manuscript received and accepted March 2, 1995. associatedreferral areaslasting 220 minutes; (2) eleva-

Address for reprints: Albert L. Waldo, MD, Division of CardioC ogy, Universiv Hospitals of Cl eveland, 1 1 100 Euclid Avenue, Cleve land, Ohio 44106.

tion of creatine kinase to twice the upper limit of normal for the given hospital in the absenceof other explanation, or the presenceof creatine kinase-MB >6% of

*See appendix for participating centers.

total; (3) development of new (>30 ms) Q waves in 22

ARRHYTHMIAS AND CONDUCTION

DISTURBANCES/o-SOTALOL

IN PATIENTS WITH iV DYSFUNCTION

1023

adjacent electrocardiographic leads, or an R wave (>30 ms) with RS ratio in lead V, >l.O (in the absenceof other causessuch as right ventricular hypertrophy or right bundle branch block). Eligible women must be either surgically sterile, postmenopausal,or using an acceptable method of contraception. Women of childbearing potential must haveanegativepregnancytestbeforerandomization.
Major exclusion criteria include: corrected QT interval >460 ms, recent (within 14 days) coronary angioplasty or bypass graft surgery, unstable angina, history of life-threatening arrhythmia unrelated to an AMI, nonischemic or severeheart failure, sick sinus syndromeor high-grade heart block without a pacemaker,concomitant antiarrhythmic agentsor drugs that prolong the QT interval, and specific electrolyte (serum potassium ~4.0 mEq/L or serum magnesium <1.5 mEq/L), renal, or liver abnormalities.
The study will consist of a screening and a doubleblind phase.During screening,a 3-channel24-hour ambulatory electrocardiographic recording will identify baseline characteristics, including supraventricular and ventricular rhythm disturbances, heart rate variability, and the presenceor absenceof signal-averagedelectro-

cardiographic abnormalities. Randomization is not contingent upon the results of the ambulatory ECG.
Eligible patients who consent to participate will enroll in the study. They will be randomly assigned to receiveatitrated doseof either d-sotalol or placebo.Doses cannot exceed200 mg twice daily for the duration of the study. For safety reasons,the dose may be reduced if clinically indicated. During follow-up, concomitant treatment with B blockers (except d,l-sotalol), digoxin, angiotensin-converting enzyme inhibitors, and calcium antagonists,is allowed.
Follow-up: Except for weekly visits for the first 2 weeks, patients will be followed every 3 months for the first year and every 4 months thereafter.Periodic clinical evaluations and laboratory studies will be obtained during the follow-up clinic visits. At month 3, a 3-channel, ambulatory electrocardiographic recording will be repeated.Patientswho discontinue the study medication will be followed for the duration of the study. The minimal follow-up period will be for 18months.A schematic of the study is depicted in Figure 1.
Ethics and informed consent: The protocol must be reviewed and approvedby institutional review boardsor equivalent committeesat eachof the participating cen-

SCREENING PHASE

* Documented MI within 6-42 days

t DocumentedMI > 42 days plus
Overt Heart Failure

\

/

LVEF 5 40%

(radionuclide ventriculography, 2D echocardiography,

or contrast ventriculography)

I I

Baseline 24-hour Holter

DOUBLE-BLIND PHASE

RANDOMIZATION

/ d-Sotalol 100 mg BID as tolerated
7 days
d-Sotalol 200 mg BID as tolerated

\ Placebo BID
as tolerated
7 days
Placebo BID
as tolerated

\

/

Follow-up

Minimum of 18 months

(including patients who discontinue study medication)

FIGURi 1. Protocol for the Survival With Oral d-Sotalol trial. High-risk survivors of a myocardial infarction are randomized
to receive either d-sotalol or placebo and
followed for 18 months. BID = twice dai-
ly; 2D = 2-dimensional; LVEF = left ventricular ejection fraction; MI = myocardial infarction.

1024 THE AMERICAN JOURNAL OF CARDIOLOGY@ VOL. 75 MAY 15, 1995

ters. The study objectives, design, risks, benefits, and transferredto anindependentstatisticalgroup which will

consequencesof trial participation areexplained to each perform the unblinded analysesfor the Data and Safety

study candidate before obtaining consent.

Monitoring Committee.

End points: The primary efficacyend point is all-cause COORDINATORS: In geographic regions, countries, or

mortality. Cardiacmortality is asecondaryendpoint. Ter- within organized consortia, coordinators will facilitate

tiary end points are cardiovascular mortality, presumed patient recruitment and communication with investiga-

arrhythmic death,nonfatal severearrhythmic events,hos- tors. They will work in conjunction with representatives

pitalizations for cardiovascularcauses,andcompositesof of the coordinating center to identify and resolve trial

these end points. An events committee blinded to treat- issues and ensure quality data collection.

ment assignmentwill review all deaths,as well as non- DRUG SUPPLY: Both active and placebo study drugs

fatal severearrhythmic events,to verify the investigators’ will bemanufactured,packaged,anddistributed by Bris-

interpretation. The final classification of an event is the tol-Myers Squibb.

responsibility of the events committee.

STEERING COMMITTEE: A Steering Committee

is

Statistical considerations: RANDOMIZATION: The trial responsible for supervision of all scientific and logistic

is double-blind. Qualified patients will be randomized aspectsof the trial. Memberswerechosenbasedon skills

centrally using a scheduleconstructedto ensurethat sim- and disciplines required to managea large multination-

ilar numbers of patients are assigned to each of the 2 al trial.

treatments at all centers. The randomization code is EVENTS COMMITTEE: The eventscommitteeis charged

available to an independent statistical center that will with the blinded review of all reported deathsand non-

perform analyses for the Data and Safety Monitoring fatal severearrhythmic events.They will evaluatethese

Committee. On an emergency basis, each investigator eventsandverify the investigators’ interpretations.In the

has accessto the individual treatment assignment by event of nonconcurrence,they will have the final deci-

removing an opaque overlay from a 3-panel, double- sion regarding the classification of events. Members of

blind label provided with the study medication.

this committee are required to have extensive cardio-

SAMPLE SIZE: The goal of the study is to enroll 6,400 vascular and clinical trial experience.

patients, all of whom will be in the final analysis. In esti- DATA AND SAFETY MONITORING COMMITTEE: The

mating sample size, the following assumptions were committeeis an independentbody of internationally rec-

made: (1) a trial duration of 3 years with a minimal ognized experts in clinical cardiology and clinical trial

patient follow-up of 18months and an averagefollow- methodology.They will periodically monitor the datato

up of 2%years, (2) group 1 (acute group) and group 2 evaluate end points and safety. As needed, they will

(remote group) patients will enter in a ratio of 2:1, (3) a make a recommendationfor changesin the study pro-

cumulative average‘mortality of 17.7%in the placebo- tocol to the steering committee.

treated patients, (4) a 20% reduction in all-cause mor- EXECUTIVE COMMITTEE: The committee comprises

tality associatedwith d-sotalol, (5) a2-sided significance selected representatives from the trial coordinators

level of 0.05, (6) a power of 90%, and (7) 10%dropouts throughout the world. They are responsible for moni-

in the d-sotalol group (patients who stop taking study toring and providing strategies for enhancing trial

medication) and 5% drop-ins in the placebo group recruitment. They meet with and advise the steering

(patients who start taking another antiarrhythmic agent). committee on issues relative to worldwide enrollment.

The samplesizeestimateis basedon the assumptionthat and study conduct.

there will be 1 intent-to-treat analysis at the conclusion

of the trial; however,during the study,the Data and Safe- DISCUSSION

ty Monitoring Committee will make periodic assess- In the western world, coronary artery diseaseis the

mentswith definedstoppingrules ,which may permit ter- leading causeof death.In up to 50% of cases,the death

mination of the trial before its completion if appropriate.6 is sudden and often occurs in patients who have sus-

For each interim analysis, the assessmenot f efficacy tained a previous myocardial infarction. Many indepen-

will be basedon a critical boundary value determinedby dentrisk factorsfor suddencardiacdeathhavebeeniden-

the procedureof Lan and DeMets.7Interim assessments tified. Some of theseinclude, alone or in combination,

of safety will use an advisory statistical boundary as the presenceof prematureventricular complexes,posi-

describedby DeMets.8 In addition, the committee will tive signal-averagedelectrocardiograms,decreasedheart

use the stochastic curtailment procedure described by rate variability, abnormalities of baroreflex sensitivity,

Pawitan and Hallstrom to assessthe likelihood that the andleft ventricular dysfunction; the last is the mostpow-

study will find a favorable result if carriedto completion. erful predictor of subsequentmortality. lQ-14Although

Organization: COORDINATING CENTER: The coordi- angiotensin-converting enzyme inhibitors can reduce

nating center is located at Bristol-Myers Squibb Phar- this mortality, the problem of sudden cardiac death re-

maceutical ResearchInstitute in Princeton, New Jersey. mains.i5-l7

In conjunction with its Europeanoffice in Brussels,Bel- The knowledge that thesepatientsmay havebaseline

gium, it is responsiblefor worldwide coordination of the ventricular rhythm disturbancesor myocardial substrate

trial, allocation of resources,communication, data man- abnormalities favoring the genesis of arrhythmias has

agement,statistical considerations,international regula- led to a stronginterestin the useof antiarrhythmic drugs.

tory compliance, and quality control. At the conclusion Somestudies,however,have raised questions about the

of the trial, the coordinating center will analyze the prudence of these agents in survivors of a myocardial

results. During the study, data files will be prepared and infarction. The Cardiac Arrhythmia Suppression Trial

ARRHYTHMIAS AND CONDUCTION DISTURBANCES/D-SOTALOL IN PATIENTS WITH LV DYSFUNCTION 1025

(CAST) unexpectedly demonstratedthat encainide, flecainide, and moricizine were harmful.18-20In addition, a recent me&analysis of mortality data from 138 trials on 98,000 survivors of myocardial infarction also found that class I (sodium channel-blocking) ant&rhythmic drugs were associatedwith increasedmortality.21Only class II (p receptor-blocking) and class III (potassium channel-blocking) drugs were associated with a decreasedmortality. Unfortunately, in a high percentageof thesepatients at risk, p blockers are not tolerated or are contraindicated.
The post-myocardialinfarction experiencewith class III agentsis quite limited, and is generally with amiodarone. Although this drug possessesmultiple antiarrhythmic actions, its ability to prolong the action potential duration and its antifibrillatory properties are considered its important electrophysiologic activities. Severalrecent trials in post-myocardial infarction patients have provided encouraging results.22-25Given these promising data, several large trials are investigating the benefit of amiodarone in reducing mortality in high-risk patients. Amiodarone, however, has important limitations related to its multiple antiarrhythmic activities, complicatedkinetics, andpotentially very seriousadverseevents.26With the worldwide incidence of coronary artery disease,the continued need to reduce mortality in high-risk patients, the promise of class III antiarrhythmic agents, and the limitations of available drugs, investigation with new class III agents is warranted.
Acknowledgment: We wish to expressour appreciation to Cheryl A. Davis for her assistancein the preparation of this manuscript.
ADDENDUM Since the submission of this paper, the SWORD tri-
al was stopped(11/l/94) becausethe boundary for harm was crossed.
APPENDIX
The following persons participate in the SWORD study. Steering Commi&x A. Waldo (Chairman), A.J. Camm, P. Friedman, D. MacNeil, B. Pitt, C. Pratt, B. Rodda, P.J. Schwartz. Coordinating Center: Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey: H. deRuyter (Study Director); Clinicians: R. Davies, D. MacNeil, S. Rajfer, M. Teter, E. V&i; Statistician: J. P&s; Administration: G. Cucinotta L. DeCa~rio. D. Knaus. C. Luciano. E. Moran. S. Moran. K. Moulton, I. Triscari. Europe:‘Clinicians: F. &rcmi, K. Jady, H. L&, K. Mel10rs, J. Pet& F. Plat, G. Paver, S. Wanless; Statistician: R. Van Frenckell; Admin. istration: C. Anthony, C. Jacobs. Austmlia/lVew Zealand: S. Humphrey. Canada: F. Char&e, L. Harvev. South Africa: S. Levenstein. Coordinators: Aw”entina: C. Bertolasi; Australia: A. Tonkin;“Czech Republic: V. Cepelak, France: P. Beaufils; Getnmny: M. Bogreffe; Israel: D. Tzivoni; Netherlands: D. Lok; New Zealand: H. White; Scandinavia: N. Edvardsson; South Africa: P. Commerford; Spain: J. Soler Soler; United States: R. DiBianco, G. Flaker, R. Henthorn, T. Heywood, J. Kluger, C. Liang, C. Pratt, A. Seals, G. Timmis. Events Committee: D. Richardson (Chairman), R. Gorlin, M. Green, A. Mitha, A. Moss, D. Myburg, N. Rehnqvist, D. Roden, B. Singh, S. Singh, A. Tonkin, P. Touboul, D. Weaver, H.J.J.
Wellens, H. White. Data and SafetMyonitoring Commi@ee: A. Hallstrom (Chair-
man), G. Breithardt, D. Bristow, S. Goldstein, D. Julian, J. Kostis. Central L&oratories: Blood Chendstrks: SmithKline Beecham, Van Nays, California; West Middlesex Laboratories, Middlesex, United Kingdom; Claymon Laboratories, Dublin, Ireland; Calab Clinical Trials Center, Stockholm, Sweden. Ambulatory Montking: Research Data Worldwide, Philadelphia., Pennsylvania. Sign&Averaged E&cfrocordiogmm/Heort Rate Variabilily: Westfalische Wilhelms-Universitat of Munster, Muster, Germany. Drug Supply: Bristol-Myers Squibb, New Brunswick, New Jersey; Moreton, United Kingdom. SWORD study centers: Argentina: A. Cagide, M. Elizari, G. Gimeno. Austrolio:

G. Aroney, P. Aylward, B. Singh, A. Thomson, A. Tonkin, W. Walsh, R. New-

man, D. Owensby, A. Pitt, I. Scott, P. Fletcher, M. Frenaux, K. Gunawardene, A.

Hamer, J. Horowitz, D. Hunt, B. Jackson, P. Garrahy, T. Campbell, T. Carmthers,

A. Calvert, F. Ekin, G. Nelson, M. Davis, M. West, G. Lane. Austria: K. Stein-

bath, D. Glogar, W. Klein, J. Slany, F. Leisch. Belgium: W. Van Mieghem, D. El

Allaf. E. Balthazar. C. De Niel. M. Delforae. P. Evrard. E. Mievis, H. Nachter-

Y

in

gaele, V. Walleghem. Canooiz: i. Caddy, W. War&a, D. Gossard, F. St-Maurice,

J. Brophy, R. Nadeau, J. Bonet, J. Boone, R. Kuritzky, C. Kerr, B. Coutu, G. O’Ham,

J. L&is, M. Dubuc, G. Tremblay, G. Proulx, C. M&Callmn, P. Dorian, M. Gard-

ner, J. McCans, M. Green, M. Sami, P. Talbot, H. Mizgala, Z. Wulffart, M. Khouri,

S. Lepage, J. Bedard, K. Hui, H. Abdollah, L. Yao, S. Kouz, M. Samson. Czech

Republic: V. Cepelak, V. Pidrman, V. Puchmayer, Brathans, J. Spinar. Chile: E.

Escobar, M. Vejar. Esfonia: R. Kolk, R. Paju, J. Voitk, H. Uuetoa. Finland: J.

Juvonen, H. Huikmi, J. Melin. Fmnce: G. Baradat, P. Beaufils, M. Delay, B.

D’Hautefeuille, C. D’Ivernois, A. Ebagosti, J. Kahn, A. Marquand, J. Medve-

dowsky, J. Michaud, A. Pisapia, J. Vedel, S. Werquin, Y. Baudouy, L. Crcccel, T.

Olive, A. Veyrat, B. Huret, A. Castaigne, E. Ferrti, G. Amat, S. Levy. Germany:

D. Kikis, D. Opherk, R. Van Essen, L. Benesch, S. Hohnloser, 1. Brachmann, L.

Goedel-Meinen, V. Hossmann, G. Bluemchen, A. H&e, A. Hepp, M. Keck, P.

Limbourg, J. Nitsch, H.L. Wedler, P. Weller, B. Loesse, J. Park, A. Heisel, A. Bran-

des, H. Simon. Greece: P. Toutouzas. Hungary: J. Borbola, K. Toth. Ireland B.

Maurer, P. Crean, J. Horgan, I. Graham W. Fennell, K. Daly, D. Sugme, P. Sul-

livan. Israel: B. Rabinowitz, D. David, 2. Schlesinger, D. Tzivoni, G. Keren, S.

Sclarovsky, A. Caspi, Y. Kishon, Markewitz, C. Shapiro, Avinadar, A. Katz, L.

Reisin, I. Zahavi, T. Rosenfeld, N. Regain, C. Lotan, J. Benhorin, T. Weiss. Italy:

E. Ambrosioni, G. Binaghi, B. Cam, M. Chiariello, E. D’Annunaio, F. Gaita, A.

Girodano, A. Lotto, A. Mares& A. Nava, M. Orlandi, A. Biagini, M. Bossi, B.

Cerri, V. De Ambroggi, P. Fazrini, E. Geraci, B. Lomanto, B. Magnani, C. Mon-

temartini, F. Nicrosini, A. Raviele, M. Radogna, P. Rizzon, G. Tumiotto, P. Ravazzi,

L. Tavazzi, C. Vecchio, G. Masini, P. Zardini, M. Palm&i, V. Rulli, A. Gemelli.

Lithurnio: A. Laucevicius, P. Zabiela. Lwemburg: C. Delagardelle. Netherlands:

A. Withagen, J. Kragten, L. ten Kate, R: Geuskens, E. Weijers, D. Lok, P. Bernink,

A. Bredero, Breedveld, Bucx, H. Fintelman, J. Henneman, J. Kingma, W. Kolsters,

0. Brand, Laxman, H. Michels, W. Muijs van de Mcer, I. Nauta, P. Van der Burgh,

B. van Vlies. L. Van Kemnen. New Zealand: H. White. S. Anandaraja, R. Luke,

P. Leslie, G.‘Lewis, S. Mkn, L. Naim, S. Reuben, D. Friedlander, H. &ram, G.

Wilkins. Po&nd: D. Wojciechowski, J. Zambrzycki, P. Achremczyk, K. Jawon.

ka, B. Dowbor, W. Tracz, L. Ceremuzynski, J. I&h, T. Kraska, M. Krzeminska-

Pakula, J. Adamus, M. Trusz-Gluza, J. Stepinska, J. Goch, K. Kawecka-Jaszcz, J.

Maciejewicz, W. Smielak-Korombel, Portogol: C. Rib&o. Russia: V. Mareyev,

Bagrov. Slovukia: S. Cagan. Slovenio: M. Horvat, J. Dobovisek, G. Voga. South

Africa: P. Commerford, P. Landless, D. Marx, A. Mitha, D. Myburgh, D. Naidoo,

M. Raiput. H. Weich. Y. Veriava. C. Schamroth. Son&z: J. Guindo, C. Mom, J.

Azpita%e, A. Castro-Beiras, J. Soier, E. De Teresa, J. Olague, F. Navarro-Lopez,

J. Diago, L. Lopez Bescos, L. Martinez Elbal, M. De Miguel, L. Saenz Cusi, J.

Reig. Sweden: N. Edvardsson, S. Ahnve, R. Norlander, g Persson, G. Ahlberg,

A. Stjema, A. Tarp, S. Bandh, R. Carlsson, G. Gustavsson, T. Fraser, M. Dellborg.

Switzerland: P. Erne, C. Cottier, A. De Torrente. United Kingdom: A. Baksi, J.

Skehan, K. Jennings, K. Charmer, J. Davies, D. Davies, T. Greenwood, S. Joseph,

T. MacDonald, A. Nathan, J. Pitt&rick, A. Rae, R. Robson, E. Rodriques, J. Silas,

G. Kaye, N. Stentiford, P. Thomas, A. Timmis, C. Ward, W. Rhoden, R. Vincent,

K. Heam. P. Siklos. M. Millar-C&z. C. Travill. A. Mourant, G. Ambepitiya, D.

Roberts, i. Oliver. ‘United States: A’: Barker, RI Bhalla, S. Borzak, M. Brodsky,

M. Carlson, A. Cohen, J. Cohen, J. Coromilas, J. Cutler, H. Dinh, S. Dyke, C. East,

D. Echt, R. Edelstein, J. Roth, G. Flaker, T. Fuchs, J. Gilman, D. Vorchheimer, K.

Kadel, R. Graf, C. Haffajee, M. Mirro, L. Basta, R. Henthorn, P. Hermany, J. Herre,

T. Heywood, J. Steinberg, T. Keltz, J. Kluger, D. Shindler, F. Kushner, T. Lejem-

tel, R. Lemery, B. Wong, S. Lewis, C. Liang, R. Mahoney, E. Raeder, D. Mann,

F. Marchlinski, D. Martin, D. McCormick, S. Mohiuddin, M. Motta, K. Nadema-

nee, A. Nichols, D. Pederson, D. Pi&m, E. Platia, P. Pool, A. Portnow, D. Russell,

M. Ryan, M. Sands, S. Schaal, A. Seals, S. Sharma, U. Shettigar, I. Singer, B.

Singh, S. Siskind, P. Willis, M. Wilson, R. Winkle, R. Zoble, R. Zusman, W. Car-

son, R. Chilton, R. DiBianco, R. Evans, G. Kubac, A. Greenspon, R. Hobbs, D.

Margolis, D. Nash, L. Petrovich, D. Rubin, R. Siegel, S. Singh, R. Kipperman, D.

Williams, K. Curry, S. Garvey, J. Hmwitz, V. Guinn, M. Meissner, S. Mehta, D.

Titus, J. Galyean IIJ, Z. Ansari, M. Ashraf, P. Callaham, M. Keselbrenner, B.

McLellan, I. Niazi, A. Riba, L. Frame, M. Lehmann, E. Farhi, A. Volgmaa, G.

Greer, N. Bittar, R. Faillace, J. Perry, R. Karlsberg, L. Chinitz, H. Golfer, J. Black,

P. Schulman, R. Feldman, J. Marshall, T. Vrobel, M. Mayo-Smith, S. Brownstein,

C. Pearson, T. Giles, J. Sacco, M. Assey, L. Bamch, P. Desbmukh, F. Leonelli, R.

Singh, J. Stratton, E. Massin, L. Padove, A. Rosenblum, L. Karagounis, S. Rabin,

J. Srebro, H. DeMots, D. Salmon, S. Kutalek, M. Leece, D. Denny, B. Lewis, M.

Effron, W. Smith, C. Massey, R. Kehoe, W. Atlas, M. Kruger, R. Heuser, D. Small,

M. Tonkon, D. Bloomfield, P. Ouyang, J. Gelormini, M. Bungo, D. Spriggs, Z.

Abedin, E. Bates, G. Burma, J. McClure, M. Zabalgoitia, J. Paris, B. Beaver, K. Vaska, S. Frank, G. Gacioch, K. Adams, J. Altamirano, R. Artwich, M. Assadi, J.

Becker, K. Browne, J. Butler, L. Cannon, F. Cecena, J. Coppola, D. Espina, K.

Gershengom, J. Ghali, M. Gittelman, D. Gohn, D. Goldman, G. Gooden, S. Gremil-

lion, B. Handler, P. Hanley, Z. Hassan, C. Hassapoyannes, L. Hattel, K. Jacobson,

B. Kennelly, A. Wang, K. Klancke, G. Kraus, P. Lebovitz, R. Levine, R. Levites,

P. Mahrer, F. McGrew III, R. Mohama, R. Muller, D. Phillips, P. P&rid, W. Polin-

ski, D. Rothrock J. Rozanski, J. Sack, K. Schwartz, Y. Shalev, J. Shanes, S. Shel-

gikar, D. Shindler, B. Shively, T. Sub, S. Swiryn, A. Ticzon, G. Timmis, S. Winters.

1026 THE AMERICAN JOURNAL OF CARDIOLOGY@ VOL. 75 MAY 15, 1995

1. Kate R, lkeda N, Yabek S, Ramaswamy K, Singh B. Electmphysiologic effects of the levo- and dextrorotatory isomers of sotalol in isolated cardiac muscle and their in viva pharmacokinetics. JAm ColZ Car&l 1986;7:116-125. 2. Patterson E, Lucchesi BR. Antifibrillatory properties of the beta-adrenergic receptor antagonists nadolol, sotalol, atenolol, and propranolol in the anesthetized dog. Phamacology 1984;28:121-129. 3. Vanoli E, Priori SC, Nakasawa H, Hirao K, Napolitano C, Diehl L: Lazzara R, Schwartz PJ. Sympathetic activation, ventricular repoltization, and q blockade: implications for the antifibrillatoIy efficacy of k+ channel blockers. JAm Coil Cardid 1995; in press. A. Gomoll AW, Bartek MJ. Comparative p-blocking activities and electrophysiologic actions of racemic sotalol and its optical isomers in anesthetized dogs. Eur J Phamacol 1986;132:123-135. 5. Yasuda SU. Barbey JT, Funck-Brentano C, Wellstein A, Woosley RL d-Sotalol reduces heart rate in viva through a P-adrenergic receptor-independent mechanism. Clin Pharmacol T&r 1993;53:43&442. 6. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. The early termination of clinical trials: causes, consequences and control with special reference to trials in the field of arrhythmias and sudden death. Circulation 1994;89:2892-2907. 7. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Bio-
met&a1983;70:659-663.
8. DeMets DL. Practical aspects in data monitoring: a brief review. Stat Med 1987;6: 753-760. 9. Pawitan Y, Hallstrom A. Statistical interim monitoring of the Cardiac Arrhythmia Suppression Trial. Stat Med 1990;9:1081-1090. 10. Bigger JT Jr, Fleiss JL, Kleiger R, Miller JP, Rolnitzky LM, and The Multicenter Post-Infarction Research Group. The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation 1984;69:25&258. 11. Kuchar DL, Thorburn CW, Sammel NL. Prediction of serious arrhy@mic events after myocardial infarction: signal-averaged electrocardiogram, Halter monitoring and radionuclide ventriculography. J Am Coil Cardiol 1987;9:53 l-538. 12. Steinberg J,.Regan A, Sciacca R, Bigger JT Jr, Fleiss J. Predicting arrhythmic events after acute MI using the signal-averaged electrocardiogram. Am J Cardiol 1992;69:13-21. 13. KIeiger RE, Miller JP, Bigger JT Jr, Moss AJ. The Multicenter Post-Infarction Research Group. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987;59:25&262. 14. LaRovere MT, Specchia G, Mortara A, Schwartz PJ. Bamreflex sensitivity, clinical correlates, and cardiovascular mortality among patients with a first myocardial infarction. Circulation 1988;78:816-824. 15. Pfeffer M, Braunwald E, May6 LA, Basta L, Brown W Jr, Cuddy TE, Daris

BR, Gelfman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Pucker M, Rouleau J, Rouleau JL, Rutherford S, Wertheimer JH, Hawkins CM, on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992;327: 677484. 16. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;
325:293-302. 17. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-828. 18. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. NEngl J Med 1989;321:40&412. 19. Echt DS, Liebson PR, Mitchell LB, Petus RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HI,, Huther ML, Richardson DW, and the CAST Investigators. Mortality and morbidity in patients receiving encainide, flecainide, or placebo; the Cardiac Arrhythmia Suppression Trial. N Engl .I Med 1991;324:781-788. 20. The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocaxlial infarction. N Engl J Med 1992;327:227-233. 21. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction: an overview of results from randomized control trials. JAMA 1993;270:1589-1595. 22. Burkart F, Pfisterer M, Kiowski W, Follath F, Burckhardt D. Effect of antiarrhythmic therapy on mortality in survivors of myocxdial infarction with asymptomatic complex ventricular arrhythmias: Base1 antiarrhythmic study of infarct surviva1 (BASIS). J Am Co2l Cardiol 1990;16:1711-1718. 23. Ceremuzynski L, Kleczar E, Krzeminski-Pakula M, Koch J, Naxtowicz E, Smielak-Korombel J, Dyduszynski A, Maciejewicz J, Zaleska T, Luzarczyk-Kedzia E, Motyka J, Paczkowska B, Sczaniecka 0, Yusuf S. Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo controlled, pilot study. .I Am Coil Cardiol 1990;20:1056-1062. 24. Cairns JA, Connolly SJ, Cent M, Roberts R. Post-myocardial infarction mortality in patients with ventricular premahlre depolarizations: Canadian amiodarone myocardial infarction arrhythmia trial pilot study. Circulation 1991;84:550-556. 25. Doval HC, Nul DR, Graxelli HO, Pen-one SV, Bortman GR, Curie1 R, for Grupo de Estodio de Sobrevida en Insuficiencia Cardiaca en Argentina (GESICA). Randomized trial of low dose amiodarone in severe congestive heart failure. Lmcet 1994;344:493--198. 26. CASCADE Investigators. Randomized antiarrhythmic dmg therapy in survivors of cardiac arrest (The CASCADE smdy). Am J Cardiol 1993;72:28&287.

ARRHYTHMIAS AND CONDUCTION DISTURBANCES/DSOTAlOL IN PATIENTS WITH LV DYSFUNCTION 1027

